157 related articles for article (PubMed ID: 36966503)
1. Challenges in the management of relapsed germ cell tumors.
Salous T; Adra N
Curr Opin Oncol; 2023 May; 35(3):218-223. PubMed ID: 36966503
[TBL] [Abstract][Full Text] [Related]
2. The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors.
Oing C; Lorch A
Oncol Res Treat; 2018; 41(6):365-369. PubMed ID: 29843143
[TBL] [Abstract][Full Text] [Related]
3. First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.
Pfister D; Oechsle K; Schmidt S; Busch J; Bokemeyer C; Heidenreich A; Heinzelbecker J; Ruf C; Winter C; Zengerling F; Kliesch S; Albers P; Oing C
World J Urol; 2022 Dec; 40(12):2853-2861. PubMed ID: 35226138
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center.
Ramanathan S; Prasad M; Vora T; Badira CP; Kembhavi S; Ramadwar M; Khanna N; Laskar S; Muckaden MA; Qureshi S; Banavali S; Chinnaswamy G
Pediatr Blood Cancer; 2023 Apr; 70(4):e30179. PubMed ID: 36645132
[TBL] [Abstract][Full Text] [Related]
5. Current Management of Refractory Germ Cell Tumors.
Abughanimeh O; Teply BA
Curr Oncol Rep; 2021 Jul; 23(9):101. PubMed ID: 34269906
[TBL] [Abstract][Full Text] [Related]
6. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W; Seidel C; Bokemeyer C; Oing C
Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Klaproth H; Kubin T; Sayer HG; Hentrich M; Welslau M; Mayer F; Kuczyk M; Spott C; Kanz L; Bokemeyer C
Br J Cancer; 2002 Sep; 87(7):729-32. PubMed ID: 12232755
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.
Rashid S; Lim L; Powles T
Curr Treat Options Oncol; 2012 Jun; 13(2):201-11. PubMed ID: 22623055
[TBL] [Abstract][Full Text] [Related]
10. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Autologous Stem Cell Transplantation (ASCT) in Relapsed/Refractory Germ Cell Tumors: Single Center Experience from Turkey.
Yildiz F; Durnali A; Eraslan E; Ilhan A; Tufan G; Aslan F; Arslan UY; Alkis N; Demirci U; Altuntas F; Oksuzoglu B
Urol J; 2020 Aug; 17(5):497-500. PubMed ID: 32869258
[TBL] [Abstract][Full Text] [Related]
12. Current medical management of patients with poor-risk metastatic germ-cell tumors.
Albany C
Curr Opin Urol; 2018 Sep; 28(5):474-478. PubMed ID: 29979236
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of testicular germ cell tumors relapse].
Carbonnaux M; Vinceneux A; Peyrat P; Fléchon A
Bull Cancer; 2020 Sep; 107(9):912-924. PubMed ID: 32653158
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.
Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C
Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452
[TBL] [Abstract][Full Text] [Related]
18. Salvage Therapy for Patients With Germ Cell Tumor.
Rashdan S; Einhorn LH
J Oncol Pract; 2016 May; 12(5):437-43. PubMed ID: 27170693
[TBL] [Abstract][Full Text] [Related]
19. The Use of Salvage Chemotherapy for Patients with Relapsed Testicular Germ Cell Tumor (GCT) in Canada: A National Survey.
Al-Ezzi EM; Zahralliyali A; Hansen AR; Hamilton RJ; Crump M; Kuruvilla J; Wood L; Nappi L; Kollmannsberger CK; North SA; Winquist E; Soulières D; Hotte SJ; Jiang DM
Curr Oncol; 2023 Jun; 30(7):6166-6176. PubMed ID: 37504318
[TBL] [Abstract][Full Text] [Related]
20. Age ≥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy.
Miller RE; Markt SC; O'Donnell E; Bernard B; Albiges LK; Beard C; Sweeney CJ
Eur Urol Focus; 2017 Dec; 3(6):621-628. PubMed ID: 28753801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]